| Year |
Citation |
Score |
| 2022 |
Scarneo S, Hughes P, Freeze R, Yang K, Totzke J, Haystead T. Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. Acs Chemical Biology. PMID 35234444 DOI: 10.1021/acschembio.1c00788 |
0.714 |
|
| 2020 |
Totzke J, Scarneo SA, Yang KW, Haystead TAJ. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biology. 10: 200099. PMID 32873150 DOI: 10.1098/Rsob.200099 |
0.711 |
|
| 2019 |
Scarneo SA, Eibschutz LS, Bendele PJ, Yang KW, Totzke J, Hughes P, Fox DA, Haystead TAJ. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research & Therapy. 21: 292. PMID 31847895 DOI: 10.1186/S13075-019-2073-X |
0.687 |
|
| 2018 |
Scarneo SA, Mansourati A, Eibschutz LS, Totzke J, Roques JR, Loiselle D, Carlson D, Hughes P, Haystead TAJ. Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific Reports. 8: 17058. PMID 30451876 DOI: 10.1038/S41598-018-35189-7 |
0.704 |
|
| 2017 |
Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, et al. Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology. 24: 1029-1039.e7. PMID 28820959 DOI: 10.1016/J.Chembiol.2017.07.011 |
0.717 |
|
| 2017 |
Crowe LB, Hughes PF, Alcorta DA, Osada T, Smith AP, Totzke J, Loiselle DR, Lutz ID, Gargesha M, Roy D, Roques J, Darr D, Lyerly HK, Spector NL, Haystead TA. A fluorescent Hsp90 probe demonstrates the unique association between extracellular Hsp90 and malignancy in vivo. Acs Chemical Biology. PMID 28103010 DOI: 10.1021/Acschembio.7B00006 |
0.524 |
|
| Show low-probability matches. |